[{"orgOrder":0,"company":"Athena Pharmaceutiques","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Levocetirizine Dihydrochloride","moa":"H1 receptor","graph1":"Immunology","graph2":"Approved","graph3":"Athena Pharmaceutiques","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Dispersible","sponsorNew":"Athena Pharmaceutiques \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Athena Pharmaceutiques \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals for Levocetirizine Dihydrochloride

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Lead Product(s) : Levocetirizine Dihydrochloride

                          Therapeutic Area : Immunology

                          Study Phase : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          Details : Levocetirizine ODT is second-generation piperazine derivative with potent H1-selective antihistaminic activity,n Improved oral bioavailability and onset of action vs. conventional oral slide form by avoiding hepatic first-pass effect.

                          Brand Name : Levocetirizine-Generic

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          October 12, 2020

                          Lead Product(s) : Levocetirizine Dihydrochloride

                          Therapeutic Area : Immunology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          Athena Company Banner